Wedge Capital Management L L P NC Has $29.93 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Wedge Capital Management L L P NC grew its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 9.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 243,357 shares of the specialty pharmaceutical company's stock after purchasing an additional 20,587 shares during the quarter. Wedge Capital Management L L P NC owned approximately 0.39% of Jazz Pharmaceuticals worth $29,933,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also modified their holdings of the company. Covestor Ltd boosted its position in shares of Jazz Pharmaceuticals by 676.5% during the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company's stock worth $51,000 after acquiring an additional 345 shares during the last quarter. Spire Wealth Management boosted its position in shares of Jazz Pharmaceuticals by 128.6% during the third quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company's stock worth $55,000 after acquiring an additional 238 shares during the last quarter. Headinvest LLC bought a new position in shares of Jazz Pharmaceuticals during the third quarter worth $56,000. Signaturefd LLC lifted its position in Jazz Pharmaceuticals by 85.7% during the third quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company's stock valued at $71,000 after purchasing an additional 252 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in Jazz Pharmaceuticals during the third quarter valued at $78,000. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ:JAZZ traded down $1.11 during trading on Monday, reaching $108.83. The stock had a trading volume of 513,929 shares, compared to its average volume of 614,017. Jazz Pharmaceuticals plc has a one year low of $106.61 and a one year high of $146.70. The company has a market capitalization of $6.86 billion, a P/E ratio of 17.78, a PEG ratio of 1.52 and a beta of 0.59. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37. The firm's 50-day simple moving average is $119.51 and its 200 day simple moving average is $122.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts' consensus estimates of $4.44 by ($0.04). The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. As a group, research analysts expect that Jazz Pharmaceuticals plc will post 16.24 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on JAZZ shares. Barclays lowered their price objective on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an "overweight" rating for the company in a research report on Friday, March 1st. Royal Bank of Canada reiterated an "outperform" rating and set a $195.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. HC Wainwright lowered their price objective on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a "buy" rating for the company in a research report on Thursday, March 14th. Piper Sandler increased their price objective on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an "overweight" rating in a research report on Wednesday, March 20th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $195.08.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the firm's stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares of the company's stock, valued at approximately $1,000,668.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the firm's stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now directly owns 8,364 shares of the company's stock, valued at approximately $1,000,668.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip L. Johnson purchased 12,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 1st. The shares were acquired at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares in the company, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.